Avelumab + Pemetrexed + Paclitaxel + Gemcitabine + Gemcitabine + Carboplatin + Cisplatin + Carboplatin + Avelumab Weekly
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
First Line Non-Small Cell Lung Cancer
Conditions
First Line Non-Small Cell Lung Cancer
Trial Timeline
Oct 29, 2015 → Jan 29, 2024
NCT ID
NCT02576574About Avelumab + Pemetrexed + Paclitaxel + Gemcitabine + Gemcitabine + Carboplatin + Cisplatin + Carboplatin + Avelumab Weekly
Avelumab + Pemetrexed + Paclitaxel + Gemcitabine + Gemcitabine + Carboplatin + Cisplatin + Carboplatin + Avelumab Weekly is a phase 3 stage product being developed by Merck for First Line Non-Small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02576574. Target conditions include First Line Non-Small Cell Lung Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02576574 | Phase 3 | Completed |
Competing Products
12 competing products in First Line Non-Small Cell Lung Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Farletuzumab + Placebo | Eisai | Phase 2 | 52 |
| Blonanserin | Sumitomo Pharma | Approved | 85 |
| HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate + nab-paclitaxel; gemcitabine | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Irinotecan Hydrochloride Liposome Injection (II); Oxaliplatin; 5Fluorouracil; Calcium folinate + nab-paclitaxel; gemcitabine | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| HRS-4642 + AG + HRS-4642 placebo + AG | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Zoledronic acid + Standard Therapy | Novartis | Approved | 85 |
| Lomustine + Romiplostim | Amgen | Phase 2 | 51 |
| Ziprasidone | Pfizer | Approved | 84 |
| AUTO CAR T cell therapy | Autolus Therapeutics | Phase 2 | 44 |
| TNX-1500 + Placebo: USP 0.9% sterile saline for injection + Keyhole Limpet Hemocyanin (KLH) | Tonix Pharmaceuticals | Phase 1 | 25 |
| Antipsychotic drugs | Brain Biotech | Pre-clinical | 15 |
| STAR-001 (LP-184) will be administered via IV infusion over 30 (± 5) minutes on Day 1 and Day 8 of each 21-day cycle. + Spironolactone (drug) | Lantern Pharma | Phase 1/2 | 33 |